Shenzhen Lifotronic Technology Co (688389) - Total Liabilities
Based on the latest financial reports, Shenzhen Lifotronic Technology Co (688389) has total liabilities worth CN¥549.45 Million CNY (≈ $80.40 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Shenzhen Lifotronic Technology Co (688389) cash conversion ratio to assess how effectively this company generates cash.
Shenzhen Lifotronic Technology Co - Total Liabilities Trend (2016–2024)
This chart illustrates how Shenzhen Lifotronic Technology Co's total liabilities have evolved over time, based on quarterly financial data. Check 688389 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Shenzhen Lifotronic Technology Co Competitors by Total Liabilities
The table below lists competitors of Shenzhen Lifotronic Technology Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guizhou Guihang Automotive Components Co Ltd
SHG:600523
|
China | CN¥865.89 Million |
|
Baticim Bati Anadolu Cimento Sanayi AS
IS:BTCIM
|
Turkey | TL10.45 Billion |
|
Farmers National Banc Corp
NASDAQ:FMNB
|
USA | $4.76 Billion |
|
Glencore PLC
LSE:GLEN
|
UK | GBX99.39 Billion |
|
Jilin Expressway Co Ltd
SHG:601518
|
China | CN¥414.27 Million |
|
Dalian Demaishi Precision Technology Co.Ltd
SHE:301007
|
China | CN¥362.01 Million |
|
Bowhead Specialty Holdings Inc.
NYSE:BOW
|
USA | $1.66 Billion |
|
Hubei Radio and Television Information Network Co Ltd
SHE:000665
|
China | CN¥5.92 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Shenzhen Lifotronic Technology Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shenzhen Lifotronic Technology Co market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenzhen Lifotronic Technology Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenzhen Lifotronic Technology Co (2016–2024)
The table below shows the annual total liabilities of Shenzhen Lifotronic Technology Co from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥845.13 Million ≈ $123.67 Million |
+58.34% |
| 2023-12-31 | CN¥533.76 Million ≈ $78.11 Million |
+41.57% |
| 2022-12-31 | CN¥377.02 Million ≈ $55.17 Million |
+74.14% |
| 2021-12-31 | CN¥216.50 Million ≈ $31.68 Million |
+48.31% |
| 2020-12-31 | CN¥145.98 Million ≈ $21.36 Million |
+12.91% |
| 2019-12-31 | CN¥129.29 Million ≈ $18.92 Million |
-9.92% |
| 2018-12-31 | CN¥143.53 Million ≈ $21.00 Million |
+16.56% |
| 2017-12-31 | CN¥123.15 Million ≈ $18.02 Million |
-2.80% |
| 2016-12-31 | CN¥126.69 Million ≈ $18.54 Million |
-- |
About Shenzhen Lifotronic Technology Co
Shenzhen Lifotronic Technology Co., Ltd. research, develops, manufactures, and markets medical devices for diagnostics, therapy, clinical medicine, skin, and human health related purposes in China. The company offers IVD products, such as HPLC, ECLIA, and hematology system; rapid test, molecular and POCT diagnostics. It also offers therapeutic products comprising respiratory and ICU, and wound ca… Read more